Baron Capital, an investment management company, released its Q4 2025 letter for its “Baron Global Opportunity Fund”. A copy of the letter can be downloaded here. Baron Global Opportunity Fund showcased a strong fourth quarter and an outstanding year. The Fund rose 6.5% (Institutional Shares) in Q4 compared to 3.3% return for the MSCI ACWI Index (the Index) and the 2.8% gain for the MSCI ACWI Growth Index, the Fund’s benchmarks. For 2025, the Fund was up 27.5%, exceeding 22.3% and 22.4% returns for benchmarks, respectively. For the Fund, the year has been defined by the challenges of de-globalization and the support from easing Federal Reserve policies, the beginnings of the AI investment cycle, and its investment in SpaceX. The Fund concluded the year with 42 investments, up from 38 the previous year, with 35 stocks accounting for 99.3% of its net assets. Please review the Fund’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, Baron Global Opportunity Fund highlighted stocks like BillionToOne, Inc. (NASDAQ:BLLN). BillionToOne, Inc. (NASDAQ:BLLN) is a precision diagnostics company specializing in molecular diagnostics. On March 05, 2026, BillionToOne, Inc. (NASDAQ:BLLN) stock closed at $72.17 per share. One-month return of BillionToOne, Inc. (NASDAQ:BLLN) was -20.35%, and its shares lost 11.82% over the past 52 weeks. BillionToOne, Inc. (NASDAQ:BLLN) has a market capitalization of $3.303 billion.
Baron Global Opportunity Fund stated the following regarding BillionToOne, Inc. (NASDAQ:BLLN) in its fourth quarter 2025 investor letter:
“We participated in the IPO of the prenatal and oncology diagnostics solutions provider, BillionToOne, Inc. The company is disrupting the market with more accurate prenatal and oncology genetic tests via its innovative Quantitative Counting Template (QCT) technology, which allows the company to accurately count the number of mutation copies at a single-gene level.
Co-Founder & CEO Oguzhan Atay said in a recent interview:9 “We want to truly bring personalized medicine into reality. We want to solve really big problems. Not just prenatal genetics, but prenatal epigenetics, preterm birth, pre-eclampsia, and also to make the biggest impact in oncology care in a century. And you know that is possible, that is essentially within reach. Our goal in the next five years is to help millions of patients, both in prenatal and oncology, and become a generational company. We want to be the first molecular diagnostics company to become an S&P 500 company.”
BillionToOne generates the vast majority of its revenue today from UNITY, which is a differentiated prenatal genetic test. Traditional prenatal tests check for chromosomal abnormalities like Down Syndrome but are less accurate for single gene inherited disorders. The standard of care screening for recessive monogenic disorders requires a DNA sample from the father (which is operationally challenging to obtain and only happens 38% of the time) and/ or defaults to a chorionic villius sampling test or amniocentesis (which carries a low but real miscarriage rate). In contrast, UNITY is a single blood draw from the mother that screens for both chromosomal problems and recessive single-gene disorders and can accurately assess the fetus’s risk of inheriting a recessive condition without requiring a sample from the father. BillionToOne has thus far captured 15% of the $2 billion-plus U.S. prenatal screening market in a short period of time, and we expect it to continue to gain share…” (Click here to read the full text)
BillionToOne, Inc. (NASDAQ:BLLN) is not on our list of 40 Most Popular Stocks Among Hedge Funds. According to our database, 23 hedge fund portfolios held BillionToOne, Inc. (NASDAQ:BLLN) at the end of the fourth quarter, compared to 0 in the previous quarter. BillionToOne, Inc. (NASDAQ:BLLN) reported total revenue of $83.5 million in Q3 2025, marking an increase of 117% from Q3 2024. While we acknowledge the risk and potential of BillionToOne, Inc. (NASDAQ:BLLN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BillionToOne, Inc. (NASDAQ:BLLN) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered BillionToOne, Inc. (NASDAQ:BLLN) and shared a list of best all-time low stocks to invest in. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
